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ABSTRACT
Background. Hypertension in blacks imposes a greater left ventricular hypertrophy, and accelerated heart failure
onset. We evaluated and compared the echocardiographically determined systolic and left ventricular diastolic
functional indices in Nigerian hypertensive patients, associated with the chronic use of ACE inhibitors, Calcium
channel blockers (CCB) or their combinations.
Methods. Ejection fraction -EF, intraventricular relaxation time (IVRT), E/A peak velocity ratio, E wave decelera-
tion time] as well as the left ventricular mass index (LVMI) was undertaken among 41 Nigerian patients with essential
hypertension only, on treatment for 4–6 months prior. The 41 patients (aged 59  10 years, 40% females) were
divided into three groups; those receiving (i) ACE inhibitors; or (ii) CCB or (iii) combination of ACEI and CCB. All
the three groups had a background of diuretic treatment for optimal blood pressure control.
Results. There were no statistically signiﬁcant differences in the mean LVMI or sitting blood pressure between
treatment groups. E/A ratio for ACEI treatment was 1.06  0.44, CCB 0.74  0.19, and for ACEI + CCB
0.87  0.26 (F = 3.29, P = 0.048 anova). The 95% conﬁdence interval for the E/A ratio on ACEI was 0.8 to 1.33.
The A wave duration time integral (AVVTi) were all abnormally large, but showed a signiﬁcant between treatment
group difference (P = 0.037, anova). The values were 21.9  4.7 for ACEI, 25.3  6.3 for CCB, and least at
20.1  3.6 cm for the ACE + CCB combination. Similarly, the IVRT was lowest and <100 ms with ACEI + CCB
being 93  18 ms, ACEI 115  23 ms, and CCB being 117  22 ms (F = 4.92, P = 0.01, anova). The 95% CI for
IVRT on ACEI + CCB was 82 to 104 ms. There were no between treatment group differences in systolic contrac-
tility, (fractional shortening or EF).
Conclusions. The results indicate that use of an antihypertensive drug regime inclusive of an ACE inhibitor (CCB)
may be associated with greater salutary effect on indices of diastolic function, (E/A > 1, lower AVVTi,
IVRT < 100 ms) even in the presence of an equivalent effect on systolic function and blood pressure.
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E
ssential hypertension remains a global
disease, which has the highest prevalence in
blacks in America [1] as well as in Sub-Saharan
African nations [2]. The target organ complica-
tions of hypertension are also both more frequent
and severe among blacks. Hypertension remains
the leading cause of cardiovascular disease [3],
congestive heart failure [4], cerebrovascular and
end-stage renal disease [5,6] as well as sudden
cardiac death and total mortality among black
patients [7–9]. The dismal effects of hypertension
on the heart of blacks in Africa and America has
been previously described using echocardiography
and pathologic samples [10–12].
Ithasbeenreportedthatatagivenlevelofblood
pressure control, blacks exhibit a more impaired
functionandgeometricdistortionsthanCaucasians
[13]. Ethnic differences both in the progression of
systolic and diastolic dysfunction, and mortality
havebeenreported,withaworseoutcomeinblacks
[14–17].Themechanismsoftheseethnicityrelated
differencesarenotknownwithcertainty,andsocio-
economic factors may contribute. However, there
is a strong suggestion of a genetic predisposition
of blacks to accelerated and severe cardiac dys-
function, based on their increased prevalence of
homozygotes for the polymorphisms of the adren-
ergic receptors Beta-1 and Alpha-2C [18]. The
imperativeforpharmacotherapeuticagentsorregi-
mens that control blood pressure and retard or
preventtargetorgandamageofhypertension,espe-
cially in blacks is thus clearly obvious. While there
are reports of such studies in Caucasians and other
populations [19–21], the impact of antihyperten-
sive treatment on echocardiographically deter-
mined cardiac systolic or diastolic function in
Sub-Saharan blacks is sparse. Further, although we
previouslyreportedonamorerationaltreatmentof
hypertension in a Nigerian tertiary center [22], it is
notcleariftheproﬁleofbloodpressurecontrolwill
translatetocardiacorganprotectioninthis“atrisk”
population.
We therefore conducted an exploratory retro-
spective study to evaluate and compare the echo-
cardiographically determined, cardiac systolic and
diastolic functional indices, associated with dif-
ferent antihypertensive treatment regimens in
Nigerian patients with essential hypertension who
have received prolonged drug therapy.
Materials and Methods
A total of 102 patients with essential hypertension
with echocardiographic records were available for
review. None of these patients had a history of
concurrent diabetes mellitus, hypertensive heart
failure (or of its history), renal disease, signiﬁcant
valvular heart disease, or angina pectoris which
were exclusion criteria. Patients were also excluded
iftheyhadpoorechocardiographicrecordings,orif
they were on a different set of antihypertensive
drug regimen, other than ACEI, CCB, or their
combination, with a diuretic background. Patients
on thiazide diuretics alone or frusemide alone were
also excluded. Of the 102 patients, 41 fulﬁlled the
inclusion criteria of being on the same indicated
antihypertensive pharmacotherapeutic regime for
at least 3–4 months, before the echocardiographic
study, and in sinus rhythm by EKG. Their blood
pressures were also well controlled, and there were
no between group statistical differences in the sys-
tolicordiastolicbloodpressures(SeeTable 1).The
Table 1 Demographic and echocardiographic dimensions, systolic and diastolic function in Nigerians with essential
hypertension on long term drug therapy with ACE—inhibitors, calcium antagonists or their combination. Mean (SD)
ACE-inhibitor
regimen
Calcium antagonist
regimen
ACE-inhibitor + Calcium
antagonist
n 13 12 16
Age(years) 58 (12) 64 (9) 55 (11)
Sex (M/F) 6/7 7/5 11/5
Systolic BP (mmHg) 143 (11) 138 (9) 141 (12)
Diastolic BP (mmHg) 88 (6) 89 (10) 84 (7)
Heart rate (min
-1) 81 (14) 82 (10) 83 (13)
LVMI (g/m
2) 125 (35) 144 (37) 149 (41)
RWT 0.52 (0.18) 0.50 (0.11) 0.61 (0.13)
LVEF (%) 79 (11) 76 (10) 72 (10)
Fractional shortening (%) 38 (8) 39 (9) 36 (7)
IVRT (ms) 115 (23) 117 (22) 93 (18)*
E/A ratio 1.06 (0.44) 0.75 (0.19) 0.87 (0.26)*
AVVTi (cm) 21.9 (4.7) 25.3 (6.3) 20.1 (3.6)*
*P < 0.05 ANOVA between groups. AVVTi = A wave velocity time integral.
BP = sitting blood pressure; RWT = relative wall thickness; LVMI = left ventricular mass index; LVEF = left ventricular ejection fraction; IVRT = Intraventricular
relaxation time; E/A ratio = ratio of early to atrial peak transmitral wave velocities.
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approvaltoconductthisretrospectivereviewofthe
clinical and echocardiographic impact of the treat-
ments, as previously reported by us [22].
An M–mode and 2 dimensional echocardio-
graphic study was undertaken using an a Siemens
sonolineG60Sultrasoundmachinewitha2.5 Mhz,
3.5 Mhz, probes, 4.2 Mhz probe for Doppler
studies. Cardiac dimensions and left ventricular
massandmassindexwerecalculatedusingthePenn
equation [23]. Systolic ejection fraction and frac-
tional shortening were calculated using standard
equations.Diastolicfunction(EarlyandAtrialpeak
velocities and their ratios E/A velocity ratio, the A
wave velocity time integral AVVTi, and the intra-
ventricular relaxation time IVRT, from the closure
oftheaorticvalvetotheopeningofthemitralvalve)
was measured using pulse- wave Doppler in which
the sample volume was placed at the tips of the
mitral valve leaﬂets in the apical 4 chamber view
[24]. The IVRT was measured as the time interval
between the end of the LV outﬂow and the start of
LVinﬂow,asindicatedbysimultaneousregistration
ofinﬂowandoutﬂowsignalsbythehighfrequency-
pulsed–wave Doppler. These diastolic parameters
were chosen because they have been shown to be
abnormallyprolongedoralteredinessentialhyper-
tension and are correlated to the level of blood
pressure [11,17,20].
The records of eligible patients (N = 41) were
then sub-divided to three groups according to
their therapeutic regime. Group A (N = 13)
were patients treated with angiotensin converting
enzyme inhibitors ; enalapril 5–10 mg daily, or lisi-
nopril 5–20 mg daily with concurrent thiazide
diuretic treatment. Group C (N = 12) received
calcium channel blockers ; amlodipine 5–10 mg
daily or rarely sustained release nifedipine 20 mg
daily,withthiazidediuretic(12.5–50 mg)toachieve
better blood pressure control. Group A + C
(N = 16), received a combination of angiotensin
converting enzyme inhibitors and calcium channel
blockers with a background of thiazide diuretics
(mostly hydrochlorothiazide 12.5–25 mg daily).
Patients in the three groups had been on these
antihypertensive medications for at least three
months, prior to the echocardiographic record.
The clinical, demographic and echocardiographic
data in the three pharmacotherapeutic groups of
treated hypertensives are summarized in Table 1.
Data is expressed as mean  standard deviation.
Statistical evaluation was by one way analysis of
variance (anova) between drug treatment groups.
This was followed by a post-hoc test (Boneferroni,
Tuckey). 95% conﬁdence limits for the difference
between groups have been quoted for selected
parameters. The null hypothesis was rejected at
P < 0.05.
Results
General
The clinical and baseline anthropometric, demo-
graphic and some echocardiographic data in the
three different antihypertensive pharmacothera-
peuticgroupsareshowninTable 1.The3different
treatmentgroupswerewellmatchedintheseverity
of left ventricular hypertrophy (LVMI), age, blood
pressures,gender(butwithaslightmaleproportion
in the combination group) and heart rate. None of
the patients had symptomatic systolic dysfunction,
andtheejectionfractionswerecomparable,withno
statistically signiﬁcant difference between groups.
Some data were omitted where echocardiographic
ﬁndings because they were unrecorded because of
unsatisfactory technical quality.
Diastolic Function
Diastolic dysfunction was assessed by mitral E/A
velocity ratio <1, A wave velocity time integral
greater than 5 cm, and prolonged IVRT > 100 ms.
The association of diastolic function with antihy-
pertensive pharmacotherapeutic class is shown in
Table 1.
E/AVelocity Ratios
There was a signiﬁcant class difference in the
mitral E/A velocity ratios (P = 0.048, anova,
F = 3.29) 37.% (5/13) of patients receiving enala-
pril or lisinopril (group A) had E/A ratio > 1. The
95% CI for E/A ratio in this group were 0.8 to
1.33. By contrast, only 8.4% (1/12) of patients
receiving calcium channel blockers, amlodipine/
sustained release nifedipine, (group C) had E/A
ratio >1. The 95% CI for the E/A in the calcium
antagonist group were 0.63 to 0.86. This value was
signiﬁcantly lower than the ACE-inhibitor group.
(See Table 1). Combined treatments (A + C) gave
E/A values that were intermediate between either
groups. See Table 1. 25% (4/16) had E/A
ratios > 1. None of the patients in any group had
“pseudonormalization”, as all those with E/A
ratio > 1, had E wave deceleration time >200 ms.
A wave velocity time integral (AVVTi): The
AVVTi was grossly increased in these groups
of chronic hypertensives. (See Table 1). There
were signiﬁcant between group differences in this
parameter according to antihypertensive pharma-
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21.9 (4.77) cm, and ACE-inhibitor combined with
CCB 20.1 (3.6), had signiﬁcantly lower AVVTi
values than Calcium channel blockers alone 25.3
(6.36). (P = 0.037, anova, F = 3.613, df = 36).
Intraventricular Relaxation Time (IVRT)
These results are shown in Table 1. There was
a highly statistically signiﬁcant difference among
the treatment groups (P = 0.013 anova, F = 4.915,
df = 36). In the ACE-inhibitor group (A), 4/13 or
31% had IVRT < 100 ms. The 95%CI for IVRT
in this group being 101–129 ms. The Calcium
channel blocker group had 2/11 or 18% of its
patients with IVRT < 100 ms. Patients on com-
bined ACEI + CCB (A + C) 9/13 or 70% had a
normal IVRT < 100 ms. The 95% CI were 82 to
104 ms, which is compatible with the normal
range.
LeftVentricular Hypertrophy and Systolic
Contractility Indices
These results are summarized in Table 1. There
were no statistically signiﬁcant differences
between groups in LVM, or LVMI or RWT.
However, the ACEI group tended to have a lower
LVMI of 125(35) g/m
2 compared to the other two
groups.
The systolic contractility indices measured as
fractional shortening or ejection fraction were all
within the normal range in the population, with no
between group differences.
Discussion
Our study was a retrospective analysis of patients
who had received treatment for 3–6 months before
echocardiographic study, and thus this study is
preliminary and only associates the echocardio-
graphic changes with speciﬁc pharmacotherapy,
but cannot establish a causal link. The three
groups of patients appeared well matched in clini-
cal or epidemiological features (Table 1).
The major differences observed between the
groups were in the diastolic function. Treatment
with ACEI was associated with a higher E/A ratio,
such that 37% had values greater than 1 with the
E-deceleration time >200 ms. By contrast only
8.4% of CCB recipients had E/A greater than 1,
but the combination of ACEI + CCB had E/A
ratio of >1 in 25% of the people. With regard to
the AVVTi, all the hypertensive patients demon-
strated increased values. However, in a similar
manner to E/A ratio, AVVTi on ACE-I alone 21.4
(4.77), or ACEI-CCB combination 20.1 (3.6) were
signiﬁcantly lower than CCB alone, 25.3 (6.36)
(P = 0.037, anova). Prolonged IVRT is another
indication of impaired diastolic relaxation, and is
abnormal if >100 ms. In these patient groups, 31%
of ACEI, and 70% of ACEI + CCB combination
had IVRT < 100 ms, compared with only 18% on
CCB alone.
Our results indicating salutary effects associated
with ACE-inhibitors or calcium channel blockers
on diastolic function accords with ﬁndings in
hypertensives, who were studied before and
after repeated echocardiographic measurements
[20,25,26]. The additive beneﬁt of CCB with
ACEI, especially with regard to the IVRT and
AVVTi accords with the notion that ACE-
inhibitors improve cardiac relaxation, and that
concurrent calcium channel blockade with ACEI
may be superior to CCB alone in our population.
These results further suggest the combined role of
the renin–angiotensin system and calcium ions, in
the process of active diastolic relaxation [27].
Previous reports indicate that left ventricular
mass and blood pressure affect the IVRT [17,28]
but the difference in IVRT in this study is not
accounted for by differences in LVMI or blood
pressures (Table 1). The apparent beneﬁcial effect
of ACEI may be because these drugs have been
shown to reduce myocardial ﬁbrosis and/or hyper-
trophy, despite minimal blood pressure change
[20,29]. This is concordant with the notion that
diastolic dysfunction may predate or be indepen-
dent of systolic function in hypertensive heart
disease [30].
Limitations of the Study
This study was retrospective in design, and the
numbers of patients were limited.
It is therefore unable to make a deﬁnitive causal
ormechanisticrelationship,betweendrugclassand
improvementindiastolicfunctionatagivenlevelof
blood pressure or systolic ejection fraction. Such
information can only be provided by future pro-
spective and randomized blinded end point study.
However, this study provides a preliminary evi-
dence associating ACEI (with or without calcium
antagonists) with a better diastolic function.
In conclusion, our preliminary study indicates
association between treatment with ACE-I (with
or without CCB) with a background of diuretic
therapy, and signiﬁcantly better indices of diastolic
function, in a group of Nigerian essential hyper-
tensive patients with left ventricular hypertrophy.
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